KR100927374B1 - Skin cell co-culture method and cell therapeutic composition using same - Google Patents

Skin cell co-culture method and cell therapeutic composition using same Download PDF

Info

Publication number
KR100927374B1
KR100927374B1 KR1020070076025A KR20070076025A KR100927374B1 KR 100927374 B1 KR100927374 B1 KR 100927374B1 KR 1020070076025 A KR1020070076025 A KR 1020070076025A KR 20070076025 A KR20070076025 A KR 20070076025A KR 100927374 B1 KR100927374 B1 KR 100927374B1
Authority
KR
South Korea
Prior art keywords
cells
culture
cell
cultured
skin
Prior art date
Application number
KR1020070076025A
Other languages
Korean (ko)
Other versions
KR20090011957A (en
Inventor
김윤영
이수희
Original Assignee
주식회사 엠씨티티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엠씨티티 filed Critical 주식회사 엠씨티티
Priority to KR1020070076025A priority Critical patent/KR100927374B1/en
Priority to PCT/KR2008/004300 priority patent/WO2009017321A2/en
Publication of KR20090011957A publication Critical patent/KR20090011957A/en
Application granted granted Critical
Publication of KR100927374B1 publication Critical patent/KR100927374B1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0697Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C12N5/0698Skin equivalents
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • A01N1/0205Chemical aspects
    • A01N1/021Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • A01N1/0205Chemical aspects
    • A01N1/0231Chemically defined matrices, e.g. alginate gels, for immobilising, holding or storing cells, tissue or organs for preservation purposes; Chemically altering or fixing cells, tissue or organs, e.g. by cross-linking, for preservation purposes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/90Serum-free medium, which may still contain naturally-sourced components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/09Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
    • C12N2502/091Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells melanocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/09Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
    • C12N2502/094Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells keratinocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/13Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323Adult fibroblasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/28Vascular endothelial cells

Abstract

Provided are a skin cell co-culture method of mixing and culturing keratinocyte, melanocyte, fibroblast, and endothelial cell which are extracted from minimal donor sites and a cell therapeutic composition using the same. Since various types of skin cells extracted from one type of donor site are mixed and co-cultured, due to a paracrine effect between cells, all the cells can be well grown even in a serum-free medium. In addition, the cells can be well grown in a medium that is not a medium specified for culture of each type of cells. In addition, the cells can be well grown even in a case where the number of cells is too small to be well grown in a separate culture. In addition, unlike the separate culture where freezing storage and thawing of melanocyte is almost not available, the mixed co-cultured cells can be well grown after the freezing storage and thawing. In addition, expression of an SMA (smooth muscle actin) which is induced in an in-vitro fibroblast culture is not induced in the mixed co-culture, so that fibroblast can be cultured without induction of differentiation. A cell therapeutic including the mixed, co-cultured skin cells can show an effective wound healing capability in comparison with conventional cell therapeutics including only the keratinocyte.

Description

피부세포 공배양 방법 및 이를 이용한 세포치료제 조성물{Co-culture method of skin cells and cell therapy composition using the same}Co-culture method of skin cells and cell therapy composition using the same}

본 발명은 피부세포의 공배양 방법에 관한 것으로, 더욱 구체적으로 최소한의 공여부위에서 분리된 표피세포(Keratinocyte), 멜라닌세포(Melanocyte), 섬유아세포(Fibroblast) 및 혈관내피세포(Endothelial cell)를 혼합배양하는 피부세포 공배양 방법과 이를 이용한 세포치료제 조성물에 관한 것이다.The present invention relates to a method for coculture of skin cells, and more specifically, to the culture of epidermal cells (Keratinocyte), melanocytes (Melanocyte), fibroblasts (Fibroblast) and endothelial cells isolated from the minimum donor site It relates to a skin cell co-culture method and a cell therapeutic composition using the same.

지금까지의 세포 배양 기술은 1cm2 미만의 공여 부위(donor site)에서는 한 가지 세포를 분리 배양하는 단계에 그쳐 있으며, 분리된 세포수의 부족으로 배양 자체의 어려움을 겪었다. 화상을 비롯한 다양한 wound 조직은 하나의 세포만으로 조성된 세포치료제로는 회복되기 어려우며, skin에 존재한 다양한 세포군이 함께 wound healing에 작용할 때 그 효과는 더 크게 나타나게 된다. 그러므로 최소한의 donor site 에서 keratinocyte, fibroblast, melanocyte를 함께 동시에 분리하여 혼합 공동 배양하는 기술을 통해서 단독 배양시에 외부로부터 첨가해 주어야 하는 cytokine 이나 growth factor의 공급 없이도 세포상호 간의 교환을 통해서 배양을 촉진시키는 환경 조성이 가능하며, 실제 피부조직과 유사한 환경을 유지 할 수 있다.Until now, cell culture technology has only been in the step of separating and culturing one cell at a donor site of less than 1 cm 2 , and suffered from the cultivation itself due to the lack of separated cells. Various wound tissues, including burns, are difficult to recover with cell therapies that consist of only one cell, and the effects are greater when various cell groups on the skin act on wound healing. Therefore, keratinocyte, fibroblast, and melanocyte are simultaneously separated and mixed co-culture at the minimum donor site to promote the culture through exchange between cells without supply of cytokine or growth factor that must be added from the outside during single culture. It is possible to create an environment and maintain an environment similar to the actual skin tissue.

이렇게 혼합 공동 배양된 세포의 경우 단독 배양된 세포에 비해서 조직 분리 후 attachment가 빨랐으며, 섬유아세포의 경우 단독 배양의 경우에 나타나는 α-smooth muscle actin을 발현 되지 않았다. 이는 배양중에 혼합 공동 배양의 경우 분화가 유도 되지 않는 것을 나타내며, in vivo 환경과 유사한 환경이 조성됨을 알 수 있다. 본 발명에 따라 살아 있는 2이상의 세포를 혼합 공동 배양하는 방법은 wound healing을 최대로 촉진시킬 수 있는 다세포치료제를 개발하는데 유용할 것이다.In the case of the mixed co-cultured cells, attachment was faster after tissue separation than in the cultured cells alone, and fibroblasts did not express α-smooth muscle actin, which was observed in the culture alone. This indicates that differentiation is not induced in the case of mixed co-culture during the culture, and it can be seen that an environment similar to the in vivo environment is formed. The method of mixed co-culture of two or more living cells according to the present invention will be useful for developing a multicellular therapeutic agent that can promote wound healing to the maximum.

따라서, 본 발명의 주된 목적은 최소한의 공여 부위에서 분리된 2가지 이상의 피부세포를 하나의 배지에서 혼합배양하는 공배양 방법을 제공하는 데 있다.Accordingly, a main object of the present invention is to provide a co-culture method of mixing two or more skin cells separated at the minimum donor site in one medium.

본 발명의 다른 목적은 상기 공배양 방법으로 배양된 피부세포들을 포함하는 세포치료제 조성물을 제공하는데 있다.Another object of the present invention to provide a cell therapy composition comprising the skin cells cultured by the co-culture method.

본 발명의 한 양태에 따르면, 본 발명은 분리된 표피세포(Keratinocyte), 멜라닌세포(Melanocyte), 섬유아세포(Fibroblast) 및 혈관내피세포(Endothelial cell)를 무혈청 배지(serum-free media)에서 혼합배양하는 것을 특징으로 하는 피 부세포 공배양 방법을 제공한다.According to an aspect of the present invention, the present invention is a mixture of isolated epidermal cells (Keratinocyte), melanocytes (Melanocyte), fibroblasts (Fibroblast) and endothelial cells (Endothelial cells) in serum-free media (serum-free media) It provides a skin cell co-culture method characterized in that the culture.

본 발명에 있어서, 바람직하게는 상기 세포들은 하나의 공여 부위(donor site)에서 분리된 것을 특징으로 하는 피부세포 공배양 방법을 제공한다. 더욱 바람직하게는, 상기 공여 부위는 공배양된 피부세포를 이식할 환자의 자가(autologous) 피부 조직을 사용하는 것을 특징으로 한다. 본 발명에 따르면, 0.5~2cm2 크기의 최소한의 공여 부위로부터 분리된 각종 피부세포를 효과적으로 공배양할 수 있다.In the present invention, preferably, the cells are co-culture method of skin cells, characterized in that separated from one donor site (donor site). More preferably, the donor site is characterized by using autologous skin tissue of the patient to transplant the cocultured skin cells. According to the present invention, it is possible to effectively co-culture various skin cells isolated from the minimum donor site of 0.5-2 cm 2 size.

본 발명에 있어서, 바람직하게는 상기 표피세포(Keratinocyte) 및 멜라닌세포(Melanocyte)는 상기 공여 부위의 표피층에서 분리하고, 상기 섬유아세포(Fibroblast) 및 혈관내피세포(Endothelial cell)는 상기 공여 부위의 진피층에서 분리된 것을 특징으로 하는 피부세포 공배양 방법을 제공한다.In the present invention, preferably, the epidermal cells (Keratinocyte) and melanocytes (Melanocyte) are separated from the epidermal layer of the donor site, and the fibroblast and endothelial cells are the dermal layer of the donor site. It provides a skin cell co-culture method characterized in that separated from.

본 발명에 있어서, 바람직하게는 상기 무혈청 배지에 단독배양시 필요한 사이토카인(cytokine)이나 성장인자(growth factor)의 공급없이 세포상호간의 물질교환(paracrine effect)에 의해 혼합배양하는 것을 특징으로 하는 피부세포 공배양 방법을 제공한다. 이러한 세포상호간의 물질교환(paracrine effect)에 의해 무혈청 배지에서도 모든 세포가 잘 자라며, 각각의 세포를 배양하기 위한 특성화된 배지가 아닌 배지에서도 세포들이 잘 자라게 된다.In the present invention, it is preferably mixed cultured by the paracrine effect between cells without supplying the cytokine (cytokine) or growth factor (growth factor) necessary for single culture in the serum-free medium. It provides a skin cell co-culture method. This paracrine effect allows all cells to grow well in a serum-free medium and to grow well in a medium that is not a specialized medium for culturing each cell.

본발명의 실시예에서 사용된 무혈청배지(KGM: Keratinocyte Growth Medium)는 원래 표피세포의 배양을 목적으로 사용되는 배지이다. 그러므로 다른 세포의 단 독배양시 배양이 잘 되지않는다. 섬유아세포의 배양의 경우 분화를 막기 위해서 bFGF를 첨가하고, 멜라닌 세포의 경우 bFGF, insulin, PMA, hydrocortisone등이 첨가된 배지를 필요로 하나, PMA은 발암성있는 물질로 알려져 있다. 본 발명의 무혈청 배지는 성장인자나 사이토카이이 완전 배제된 배지는 아니지만, 각각의 단독배양에서 반드시 필요로 하는 bFGF, PMA와 같은 인자들이 배제된 상황에서도 공동배양의 경우 배양이 가능하다.Serum-free medium (KGM: Keratinocyte Growth Medium) used in the examples of the present invention is a medium originally used for culturing epidermal cells. Therefore, the culture of other cells alone is not well cultured. Fibroblast cultures require bFGF to prevent differentiation and melanocytes require bFGF, insulin, PMA, hydrocortisone, etc., but PMA is known to be carcinogenic. The serum-free medium of the present invention is not a medium in which growth factors or cytokines are completely excluded, but co-cultivation is possible even in a situation where factors such as bFGF and PMA, which are necessary for each single culture, are excluded.

본 발명에 있어서, 바람직하게는 상기 표피세포+멜라닌세포 : 섬유아세포+혈관내피세포의 비율이 15:1 내지 25:1로, 가장 바람직하게는 20:1로 혼합배양하는 것을 특징으로 하는 피부세포 공배양 방법을 제공한다. 본 발명의 실시예에서는 여러 가지 배율의 공동배양시험을 여러번 진행한결과 20:1(표피세포+멜라닌세포 : 섬유아세포+혈관내피세로)의 비율에서 모든 세포가 가장 잘자라는 것을 확인했습니다. 표피세포수가 상기 범위 이상일 경우는 섬유아세포의 부족으로 ECM 성분이 충분히 생성되지 않아서 표피세포의 부착이 잘 되지 않으며, 섬유아세포의 수가 상기 범위 이상일 경우에는 섬유아세포 배양에 필수적이 혈청이 없는 배지에서 표피세포의 물질교환의 통해서 자라야 하기 때문에 무혈청 배지에서 배양하였을 경우에 나타나는 섬유아세포의 뭉침현상이 나타나는 것을 확인할 수 있었습니다. In the present invention, preferably the ratio of epidermal cells + melanocytes: fibroblasts + vascular endothelial cells is 15: 1 to 25: 1, most preferably 20: 1 skin cells, characterized in that the mixed culture Provide a coculture method. In the embodiment of the present invention, a number of co-culture tests at various magnifications showed that all cells grew best at a ratio of 20: 1 (epidermal cells + melanocytes: fibroblasts + vascular endothelial cell). If the number of epidermal cells is more than the above range, the lack of fibroblasts does not produce enough ECM components, so the adhesion of epidermal cells is not good. Since the cells must be grown through mass exchange, it was confirmed that clustering of fibroblasts appeared when cultured in serum-free medium.

본 발명에 있어서, 바람직하게는 섬유아세포의 단독배양에서 유도되어지는 SMA(smooth muscle actin)의 발현이 유도되지 않는 것을 특징으로 하는 피부세포 공배양 방법을 제공한다. 상기 SMA(smooth muscle actin)이 발현되지 않는다는 것은 분화가 유도되지 않은 섬유아세포의 배양이 가능함을 의미한다.In the present invention, it provides a skin cell co-culture method, characterized in that the expression of smooth muscle actin (SMA) which is preferably induced in the culture of fibroblasts alone is not induced. Not expressing the SMA (smooth muscle actin) means that the differentiation-induced fibroblasts can be cultured.

본 발명에 있어서, 바람직하게는 단독배양시 동결보관과 해동후에 잘 자라지 않던 멜라닌세포가 동결보관과 해동후에도 잘 자라는 것을 특징으로 하는 피부세포 공배양 방법을 제공한다. 멜라닌세포는 단독배양시에는 질소탱크에서 저장(동결보관)이 되지 않으며 다시 해동하여 배양시에는 거의 모두 사멸하였으나, 본 발명에 따라 혼합 공동배양한 경우에는 동결보관과 해동후에도 잘 자라는 것을 확인하였다.In the present invention, preferably, melanocytes that do not grow well after cryopreservation and thawing during culturing alone provide a method for co-culture of skin cells, characterized in that they grow well even after cryopreservation and thawing. Melanocytes were not stored (frozen storage) in nitrogen tanks when cultured alone and almost all died upon culturing again, but when mixed co-cultured according to the present invention, they grew well even after freezing storage and thawing.

본 발명의 다른 양태에 따르면, 본 발명은 상기 본 발명의 공배양 방법에 따라 공배양된 표피세포(Keratinocyte), 멜라닌세포(Melanocyte), 섬유아세포(Fibroblast) 및 혈관내피세포(Endothelial cell)를 포함하는 상처치유용(wound healing) 세포치료제 조성물을 제공한다. 상기 상처치유용이란 피부의 외상이나 화상으로 인한 상처 또는 멜라닌세포의 소실 혹은 멜라닌 생산의 감소에 따르는 저색소화(hypopigmentation) 또는 백반증(vitiligo) 증상을 치유하거나 완화하는 것을 의미한다. 본 발명의 세포치료제는 표피세포(Keratinocyte)만을 분리 배양하여 화상부위에 뿌리거나 붙이는 종래의 세포치료제보다 월등한 상처치유능력을 보여주었다.According to another aspect of the present invention, the present invention comprises epidermal cells (Keratinocyte), melanocytes (Melanocyte), fibroblasts (Fibroblast) and endothelial cells (Endothelial cells) co-cultured according to the co-culture method of the present invention It provides a wound healing cell therapy composition. The wound healing means to heal or alleviate the symptoms of hypopigmentation or vitiligo caused by a wound or a loss of melanocytes or a decrease in melanin production due to trauma or burn of the skin. The cell therapy agent of the present invention showed superior wound healing ability than the conventional cell therapy agent that separates and cultures only epidermal cells (Keratinocytes) and sprinkles or attaches to the burn site.

본 발명의 세포치료제 조성물은 당업계에 일반적인 제형, 예컨대, 주사제, 스프레이, 매트릭스, 또는 필름의 형태로 제조될 수 있으며, 외과수술적으로 피부손상부위에 직접 이식하거나, 스프레이의 형태로 피부손상부위에 도포하거나, 매트릭스나 필름의 형태로 피부손상부위에 적용하거나, 정맥에 투여된 후 피부손상부위로 이동할 수 있다. 본 발명의 조성물 중 공배양된 세포는 질병의 유형, 투여경로, 환자의 나이 및 성, 및 질병의 정도에 따라 변할 수 있으나, 바람직하게는 평균 성인의 경우 104 내지 108 cells를 투여한다.The cell therapy compositions of the present invention may be prepared in the form of formulations common in the art, such as injections, sprays, matrices, or films, which may be surgically implanted directly into the skin injuries, or in the form of sprays. It can be applied to, or applied to, the skin injury in the form of a matrix or film, or transferred to the skin injury after administration to a vein. Cells co-cultured in the composition of the present invention may vary depending on the type of disease, route of administration, age and sex of the patient, and degree of disease, but preferably 10 4 to 10 8 cells for the average adult.

이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하기로 한다. 이들 실시예는 단지 본 발명을 예시하기 위한 것이므로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다.Hereinafter, the present invention will be described in more detail with reference to Examples. Since these examples are only for illustrating the present invention, the scope of the present invention is not to be construed as being limited by these examples.

실시예 1. 피부조직에서 일차세포 분리 및 배양Example 1.Isolation and Culture of Primary Cells from Skin Tissue

외과 수술로 얻어진 약 1cm2의 포피조직(foreskin)을 5㎟ 이하의 작은 조직으로 자르고 5% penicillin-streptomycin(PS)이 포함된 차가운 D-PBS에서 10번 세척한다. Dispase(P-3417, Sigma)를 넣어서 37℃ water bath에서 2시간 효소반응을 시킨 후 10㎖ 5% PS-PBS가 담긴100㎜ dish에 옮기고 핀셋으로 표피층와 진피층를 분리한다.About 1 cm 2 of foreskin obtained by surgery is cut into small tissues of 5 mm 2 or less and washed 10 times in cold D-PBS containing 5% penicillin-streptomycin (PS). Add Dispase (P-3417, Sigma) and perform enzymatic reaction in 37 ℃ water bath for 2 hours, transfer to 100㎜ dish containing 10ml 5% PS-PBS, and separate epidermal and dermal layers with tweezers.

표피세포(Keratinocyte)와 멜라닌세포(Melanocyte) 분리하기 위해서 분리된 표피층을 15㎖ tube에 옮겨 Trypsin-EDTA를 넣고 37℃ water bath에서 1시간 반응시킨다. 50㎖ tube에 100㎛ cell strainer을 올려 넣고서, Trypsin-EDTA반응액을 걸려낸다. Trypsin-EDTA 작용을 중단시키기 위해서 같은 양의 FBS를 넣고, 1,200rpm, 4℃에서 5분간 원심분리한다. 상층액을 제거하고 침전된 표피세포(Keratinocyte)와 멜라닌세포(Melanocyte)를 무혈청배지인 KGM(Keratinocyte Growth Medium: KBM(Keratinocyte Basal Medium, 2㎖ BPE, 500㎕ Insulin, 500㎕ hEGF, 500㎕ GA-1000, 500㎕ Hydrocortisone)(Cambrix사, USA)를 넣어 현탁시키 후 세포수를 샌다.In order to separate epidermal cells (Keratinocyte) and melanocytes (Melanocyte), transfer the separated epidermal layer into a 15ml tube, add Trypsin-EDTA, and react for 1 hour in a 37 ℃ water bath. Put a 100㎛ cell strainer on a 50ml tube and quench the Trypsin-EDTA reaction solution. To stop Trypsin-EDTA action, add the same amount of FBS and centrifuge for 5 min at 1,200 rpm, 4 ° C. Remove the supernatant and precipitate the epidermal cells (Keratinocyte) and melanocytes (Keratinocyte Growth Medium: KBM (Keratinocyte Basal Medium, 2ml BPE, 500µl Insulin, 500µl hEGF, 500µl GA) -1000, 500µl Hydrocortisone (Cambrix, USA) is added to the suspension and the cell number is leaked.

섬유아세포(Fibroblast)와 혈관내피세포(Endothelial cell) 분리하기 위해서 분리된 진피층을 가능한 잘게 가위로 잘라주고 50㎖ tube에 옮겨 0.1% collagenas를 넣고 37℃ water bath에서 1시간 반응시킨다. collagenase 효소반응을 제거하기 위해서 FGM(Fibroblast Growth Medium media: FBM(Fibroblast Basal Medium), 10㎖ FBS, 500㎕ Insulin, 500㎕ rhFGF-B, 500㎕ GA-1000)을 넣어 1,200rpm , 4℃ , 5분간, 2회 원심 분리하여 상층액을 제거한다. To separate the fibroblast and endothelial cells, cut the separated dermal layer with finely cut scissors, transfer to 50ml tube, add 0.1% collagenas, and react for 1 hour in 37 ℃ water bath. To remove the collagenase enzyme reaction, FGM (Fibroblast Growth Medium media: FBM (Fibroblast Basal Medium), 10ml FBS, 500µl Insulin, 500µl rhFGF-B, 500µl GA-1000) was added at 1,200rpm, 4 ℃, 5 For two minutes, the supernatant is removed by centrifugation twice.

실시예 2. 표피세포(Keratinocyte), 멜라닌세포(Melanocyte), 섬유아세포(Fibroblast), 혈관내피세포(Endothelial cell)의 혼합 배양Example 2 Mixed Culture of Epidermal Cells (Keratinocyte), Melanocytes (Melanocyte), Fibroblasts, Endothelial Cells

표피층에서 분리된 표피세포(Keratinocyte), 멜라닌세포(Melanocyte)와 진피층에서 분리된 섬유아세포(Fibroblast), 혈관내피세포(Endothelial cell)를 20:1 비율로 KGM에서 초기 일차배양한다. 처음에 포피세로로부터 세포를 분리할 경우에는 표피세포+멜라닌세포가 함께 표피층에서 분리되고 진피층에서는 섬유아세포와 혈관내피세포가 함께 분리되기 때문에 초기 일차배양에서의 세포접종 비율은 표피세포+멜라닌세포: 섬유아세포+혈관내피세포의 비율이 20:1일 경우 공동 배양에 가장 유리한 것을 여러 시험결과로 확인하였다. 계대배양은 Trypsin-EDTA에 3분간 반응시켜서 표피세포를 제외한 멜라닌 세포와 섬유아세포, 혈관내피세포를 배양접시 로부터 떼어내고, 10분간 더 반응시켜서 표피세포를 떼어낸다. 각각의 Trypsin-EDTA 반응액에서 FBS를 첨가하여 효소반응을 중지시키고, 원심분리하여 상층액을 제거하고, 세포 현탁액을 만들어 세포수를 샌다. 3×105개의 표피세포와 1/20 (1.5x104)의 비율로 멜라닌 세포, 섬유아세포, 혈관내피세포가 혼합된 세포 현탁액을 섞어서 KGM에서 혼합배양한다. 이차 계대 배양의 경우는 trypsin-EDTA 처리에 의해서 3분내로 분리되어지는 멜라닌세포와 섬유아세포, 혈관내피세포가 함께 분리되고, 10분더 처리된 후에 분리되는 표피세포가 단독으로 분리된다. 따라서 계대배양의 경우에는 표피세포 : 섬유아세포+멜라닌세포+혈관내피세포 의 비율이 20:1 일 경우 공동 배양에서 가장 유리한 것을 확인하였다. 같은 방법으로 계대수 4까지 계대배양하면서 세포 모양과 세포수를 관찰하였다. 도 1은 본 발명에 따라 혼합배양한 일차배양(P=1) 및 계대배양(P=2~5)에서의 세포 모양을 관찰한 사진이다. Epidermal cells (Keratinocyte), melanocytes (Melanocyte) and the fibroblasts (Fibroblast) and Endothelial cells (Endothelial cells) isolated from the epidermal layer is isolated from the epidermal layer in the initial primary culture in 20: 1 ratio. In the initial separation of cells from the epidermal cell, epidermal cells and melanocytes are separated from the epidermal layer and fibroblasts and vascular endothelial cells are separated from the dermal layer. When the ratio of fibroblasts and vascular endothelial cells is 20: 1, it was confirmed by the test results that the most favorable for co-culture. Subcultures were allowed to react with Trypsin-EDTA for 3 minutes to separate melanocytes, fibroblasts, and vascular endothelial cells, except for epidermal cells, from the culture dish, followed by further reaction for 10 minutes to separate epidermal cells. In each Trypsin-EDTA reaction solution, FBS was added to stop the enzyme reaction, centrifugation to remove the supernatant, and a cell suspension was made to drain the cell number. 3 × 10 5 epidermal cells and a cell suspension containing melanocytes, fibroblasts, and vascular endothelial cells at a ratio of 1/20 ( 1.5 × 10 4 ) are mixed and cultured in KGM. In the secondary passage culture, melanocytes, fibroblasts and vascular endothelial cells, which are separated within 3 minutes by trypsin-EDTA treatment, are separated together, and epidermal cells separated after 10 minutes of treatment are separated. Therefore, in the case of subculture, the ratio of epidermal cells: fibroblasts + melanocytes + vascular endothelial cells was found to be most advantageous in co-culture. In the same manner, cell culture and cell number were observed while subcultured to passage number 4. 1 is a photograph observing the cell shape in the primary culture (P = 1) and subculture (P = 2 to 5) mixed culture in accordance with the present invention.

[표 1] 일차배양(P=1) 및 계대배양(P=2~5)에서의 세포수TABLE 1 Cell number in primary culture (P = 1) and subculture (P = 2 ~ 5)

표피세포 Epidermal cells 멜라닌세포 Melanocytes 섬유아세포 Fibroblast 혈관세포Vascular cells 일차배양Primary culture 1.80E+061.80E + 06 8.00E+058.00E + 05 P2 P2 6.80E+056.80E + 05 7.40E+057.40E + 05 P3P3 4.24E+064.24E + 06 1.95E+061.95E + 06 P4P4 1.04E+061.04E + 06 3.00E+053.00E + 05 P5P5 2.40E+052.40E + 05 1.55E+051.55E + 05

이와 대조적으로, 각각 포피조직에서 초기 분리된 섬유아세포(1x 106 cell)와 표피세포(1x 106 cell)를 단독으로 KGM 배지에서 배양하였을 경우 세포 모양을 관찰하였다. 도 2의 A와 B는 각각 포피조직에서 초기 분리된 섬유아세포와 표피세포를 단독으로 KGM 배지에서 배양하였을 경우의 사진이다. A.에서 섬유아세포는 serum free KGM에서 건강하게 자라지 못하고, 서로 뭉치는 경향을 보였으며, B.에서 표피세포 단독배양은 배양접시에 전혀 attachment하지 못함을 알 수 있었다. 도 2의 C는 표피세포+멜라닌세포(1x 106 cell) : 섬유아세포+혈관내피세포(5x 104 cells)를 20:1의 비율로 KGM에서 공동배양한 사진이다. 본 발명에 따라 공동 배양한 경우 두 세포 모두 잘 자람을 알 수 있었다. 도 3의 D.E.F.는 세포의 혼합 비율을 달리하여 시험한 결과이다. 각각 표피세포+멜라닌세포: 섬유아세포+혈관내피세포의 비율을 10:1(D), 20:1(E), 30:1(F)로 하여 비교하였다. 세포관찰 결과 20:1 비율에서 모든 세포가 가장 잘 배양되는 것을 알수 있었다.In contrast, when the fibroblasts (1x 10 6 cells) and epidermal cells (1x 10 6 cells), which were initially isolated from the foreskin tissue, were cultured in KGM medium alone, cell shapes were observed. 2A and 2B are photographs when the fibroblasts and epidermal cells initially isolated from the foreskin tissue were cultured alone in KGM medium. In A. fibroblasts did not grow healthy in serum-free KGM and showed a tendency to aggregate together. In B., epithelial cells alone did not attach to the culture dish at all. 2C is a photograph of co-culture of epidermal cells + melanocytes (1x 10 6 cells): fibroblasts + vascular endothelial cells (5x 10 4 cells) in KGM at a ratio of 20: 1. When co-cultured according to the present invention, both cells grew well. DEF of Figure 3 is a test result by varying the mixing ratio of the cells. The ratio of epidermal cells + melanocytes: fibroblasts + vascular endothelial cells was compared with 10: 1 (D), 20: 1 (E), and 30: 1 (F), respectively. Cell observation revealed that all cells were best cultured at a 20: 1 ratio.

혼합 공동 배양은 외부로 부터 cytokine이나 growth factor의 공급없이 세포서로간의 상호 교환을 통해서 세포배양이 가능하기 때문에 serum-free media(KGM)에서의 배양이 더 유리하며, serum 이 첨가된 배지(E-media)의 경우는 섬유아세포와 같이 serum에 의해서 성장이 촉진되는 세포의 배양 속도만을 증가시키기 때문에 상대적으로 다른 세포의 상태가 나빠질 수 있으며, 세포 서로간의 분열속도 조화가 깨지는 결과를 가져온다. 이를 증명하기 위해, 10% serum이 첨가된 E-media (Sigma, Poole, U.K.)를 사용하여 단독 또는 혼합 배양하였다. 도 4에서 보여지듯이, serum이 첨가된 배지에서는 표피세포 단독배양과 표피세포와 섬유아세포가 함께 배양된 경우 모두 세포 배양이 제대로 되지 못했으며, serum이 없는 배지(KGM) 에서의 배양이 두 경우 모두 좋았다. Mixed co-cultivation is more advantageous in culturing in serum-free media (KGM) because it is possible to culture cells by mutual exchange between cells without supply of cytokine or growth factor from the outside. In the case of media), as it increases only the culture rate of cells promoted by serum, such as fibroblasts, the condition of other cells may worsen, resulting in a breakdown of the division rate of cells. To demonstrate this, 10% serum-added E-media (Sigma, Poole, U.K.) was used alone or mixed culture. As shown in FIG. 4, in the medium to which serum was added, both epithelial cells alone and epithelial cells and fibroblasts were not cultured properly, but both were cultured in serum-free medium (KGM). it was good.

실시예 3. 혼합공동 배양된 세포의 저장과 해동Example 3. Storage and Thawing of Mixed Co-Cultured Cells

표피세포 : 섬유아세포, 멜라닌 세포, 혈관세포 비율이 4:1 또는 20:1 로 전체 세포 수 1 × 106 cells 로 freezing media(KGM : FBS : DMSO = 5: 4: 1)에 현탁하여 -70℃ 냉동고에서 하루 방치하고서, 다음날 액체질소에 넣어서 장기 보관한다. 저장 후 10일후에 다시 녹인 후 배양접시에 접종하여 세포 생존율과 세포 상태를 확인하고 형광염색하여 각각의 세포가 정상적으로 생존하는 것을 확인하였다. 도 5는 본 발명에 따라 혼합공동 배양된 세포들의 동결보관 및 해동후 세포 생존율과 세포 상태를 확인한 사진이다. 이로부터 단독배양시 동결보관과 해동후에 잘 자라지 않던 멜라닌세포(HMB45)가 동결보관과 해동후에도 잘 자라는 것을 알 수 있었다.Epidermal cells: Fibroblasts, melanocytes, and vascular cells with a ratio of 4: 1 or 20: 1, suspended in freezing media (KGM: FBS: DMSO = 5: 4: 1) at a total cell count of 1 × 10 6 cells. Leave in a freezer for one day, put in liquid nitrogen the next day and stored for a long time. 10 days after storage, the cells were dissolved again, and then inoculated in a culture plate to confirm cell viability and cell status, and fluorescence staining confirmed that each cell normally survived. 5 is a photograph confirming cell viability and cell state after cryopreservation and thawing of mixed co-cultured cells according to the present invention. From this, melanocytes (HMB45), which did not grow well after cryopreservation and thawing, were found to grow well after cryopreservation and thawing.

실시예 4. 혼합공동 배양된 세포의 면역 형광염색법 Example 4. Immunofluorescence Staining of Mixed Co-Cultured Cells

혼합 공동 배양된 세포의 확인시험을 위하여 각각의 세포에서만 발현되는 marker를 면역형광 염색 방법으로 측정하였다. 표피세포 : 섬유아세포 + 멜라닌세포 + 혈관내피세포를 20:1의 비율로 혼합공동 배양된 세포를 차가운 methanol을 첨가하여 4℃에서 10분간 반응하여 고정시킨 후, 0.2% TritonX-100이 첨가된 PBS에 10min간 상온에서 shaking하면서 반응시켜서 Permeabilization시켰다. PBS에서 5min shaking하여 3회 세척한 후, 20% NGS(normal goat serum)이 첨가된 PBS로 상온에서 1시간 반응시키고, 표피세포, 멜라닌세포, 섬유아세포, 혈관내피세포 marker인 cytokeratin 14, HMB45, vimentin, vWF(Von Willebrand Factor) 항체로 상온에서 2시간 동안 반응시킨다. PBS에서 5min shaking하여 3회 세척한 후, 형광 dye가 결합된 secondary antibody(Cy2, Texas Red)를 상온에서 1시간 30분동안 반응시킨다. PBS에서 5min shaking하여 3회 세척한 후, 핵염색을 위해서 DAPI(Sigma D-9542)에서 5분간 반응시키고, Vectashield로 (Vector Lab.) Mounting한다. 마지막으로 Leica사의 MacroFluoTM 형광현미경을 통해서 관찰하였다. 도 6은 계대수 2의 혼합 공동 배양한 세포를 면역 형광 염색한 사진이다. 빨간색 화살표: Melanocyte, 파란색 화살표: Fibroblast. 계대수 2의 혼합 공동 배양한 세포를 면역 형광 염색한 결과 멜라닌 세포(HMB45)가 존재함을 알 수 있다. 도 7은 계대수 2의 혼합 공동 배양한 세포를 면역 형광 염색한 사진이다. 계대수 2의 혼합 공동 배양한 세포를 면역 형광 염색한 결과 혈관내피세포(vWF)가 존재함을 알 수 있다. 도 8은 계대수 3의 혼합 공동 배양한 세포를 면역 형광 염색한 사진이다. 빨간색 화살표: Melanocyte, 파란색 화살표: Fibroblast. 계대수 3의 혼합 공동 배양한 세포를 면역 형광 염색한 결과 멜라닌 세포(HMB45), 표피세포(CK14)가 존재함을 알 수 있다. 도 9는 계대수 3의 혼합 공동 배양한 세포를 면역 형광 염색한 사진이다. 계대수 3의 혼합 공동 배양한 세포를 면역 형광 염색한 결과 멜라닌 세포(HMB45), 표피세포(CK14), 섬유아세포(vimentin)가 존재함을 알 수 있다. 도 10은 계대수 4의 혼합 공동 배양한 세포를 면역 형광 염색한 사진이다. 빨간색 화살표: Melanocyte, 파란색 화살표: Fibroblast. 계대수 4의 혼합 공동 배양한 세포를 면역 형광 염색한 결과 멜라닌 세포(HMB45)가 존재함을 알 수 있다.For identification of mixed co-cultured cells, markers expressed only in each cell were measured by immunofluorescence staining. Epidermal cells: Fibroblasts + melanocytes + vascular endothelial cells were fixed by co-cultured cells at a ratio of 20: 1 with cold methanol for 10 minutes at 4 ° C, followed by PBS with 0.2% TritonX-100. Permeabilization by reacting while shaking at room temperature for 10min. After washing 3 times with 5 min shaking in PBS, the reaction was performed at room temperature for 1 hour with PBS added with 20% NGS (normal goat serum), and cytokeratin 14, HMB45, which are markers for epidermal cells, melanocytes, fibroblasts, and vascular endothelial cells. Reaction with vimentin, vWF (Von Willebrand Factor) antibody at room temperature for 2 hours. After washing three times by shaking for 5 minutes in PBS, the secondary antibody (Cy2, Texas Red) to the fluorescent dye is reacted for 1 hour 30 minutes at room temperature. After washing 3 times by shaking for 5 minutes in PBS, and then reacted for 5 minutes in DAPI (Sigma D-9542) for nuclear staining, and mounted with Vectashield (Vector Lab.). Finally, Leica's MacroFluo TM fluorescence microscope was used. 6 is a photograph of immunofluorescence staining of cells co-cultured with passage number 2. Red arrow: Melanocyte, Blue arrow: Fibroblast. Immunofluorescence staining of mixed coculture cells of passage number 2 shows that melanocytes (HMB45) are present. 7 is a photograph of immunofluorescence staining of cells co-cultured with passage number 2. Immunofluorescence staining of cells co-cultured with passage number 2 shows that vascular endothelial cells (vWF) are present. Fig. 8 shows immunofluorescence staining of mixed co-cultured cells of passage number 3. Red arrow: Melanocyte, Blue arrow: Fibroblast. Immunofluorescence staining of the mixed coculture cells of passage 3 showed that melanin cells (HMB45) and epidermal cells (CK14) exist. 9 is a photograph of immunofluorescence staining of cells co-cultured with passage number 3. Immunohistofluorescence staining of passage co-cultured cells of passage 3 indicates that melanocytes (HMB45), epidermal cells (CK14) and fibroblasts (vimentin) are present. 10 is a photograph of immunofluorescence staining of cells co-cultured with passage number 4. Red arrow: Melanocyte, Blue arrow: Fibroblast. Immunofluorescence staining of cells co-cultured with passage number 4 shows that melanocytes (HMB45) are present.

도 11은 본 발명에 따른 혼합 공동 배양한 세포에서 α-SMA(α-smooth muscle actin)이 발현되는지를 확인한 사진이다. 섬유아세포 단독배양(p=2) 그림을 제외하고 모두 20:1 (표피세포 : 섬유아세포 + 멜라닌세포 + 혈관내피세포)비율의 공동 배양 결과이다. 섬유아세포의 단독배양에서 발현되는 α-SMA(α-smooth muscle actin)이 혼합 공동 배양에서는 발현되지 않았다. 따라서, 본 발명에 따른 혼합 공동 배양은 섬유아세포의 분화를 억제시킴을 알 수 있다. 11 is a photograph confirming that α-SMA (α-smooth muscle actin) is expressed in mixed co-cultured cells according to the present invention. Fibroblasts alone culture (p = 2) Except for the figure, all of the results were co-cultured at a ratio of 20: 1 (epidermal cells: fibroblasts + melanocytes + vascular endothelial cells). Α-Smooth muscle actin (α-SMA) expressed in the culture of fibroblasts alone was not expressed in the mixed co-culture. Therefore, it can be seen that the mixed co-culture according to the present invention inhibits the differentiation of fibroblasts.

실시예 5. 혼합 공동 배양된 세포의 in vivo 피부형성능 시험 Example 5. In vivo skin formation test of mixed co-cultured cells

실시예 2에 따라 제조된 혼합 공동배양된 세포의 현탁액이 흐르는 것을 방지하고, 누드 마우스 조직이 빠르게 치유되는 것을 막기 위해서 3㎖ 주사기 손잡이 부위를 적당한 크기 (높이 1㎝)로 절단하여 syringe splint를 제작한다. 누드 마우스를 마취시키고, 등 부분에 피부를 절취하여 syringe split 삽입한다. syring split 고정하고 세포배양액 누출 방지하기 위해서 purse-string suture를 한다. 혼합공동배양 현탁액를 넣어 준다. 외부로부터 오염을 방지하고 피부 환경을 유지하기 위해서 Tegaderm(3M)를 붙이고, 항생제를 7일간 투여하였다. Teraderm과 syringe splint는 시술 5일 후에 탈락 시키고, 하루동안 상처를 open된 상태로 유지 시켰다. 도 12은 본 발명에 따라 혼합 공동 배양된 세포의 누드 마우스에서의 in vivo 피부형성능을 관찰한 사진이다.In order to prevent the suspension of the mixed co-cultured cells prepared according to Example 2 and to prevent the rapid healing of nude mouse tissue, a 3 ml syringe handle was cut to an appropriate size (1 cm in height) to prepare a syringe splint. do. Anesthetize the nude mouse, cut the skin on the back and insert the syringe split. Secure the syring split and purse-string suture to prevent cell culture fluid leakage. Add the mixed coculture suspension. To prevent contamination from outside and maintain the skin environment, Tegaderm (3M) was added and antibiotics were administered for 7 days. Teraderm and syringe splint were dropped 5 days after the procedure and the wound was left open for a day. Figure 12 is a photograph observing the in vivo skin formation ability in nude mice of mixed co-cultured cells according to the present invention.

실시예 6. in vivo 형성된 피부조직의 면역 염색법Example 6 Immunostaining of Skin Tissues Formed In Vivo

혼합 공동 배양된 세포의 in vivo 피부형성능 시험을 진행하고, 누드 마우스를 sacrifice한 후, 형성된 조직을 포르말린에 고정하여 paraffin 조직 절편을 만든다. Deparaffinization과 Hydration과정을 거친 후, 항원 항체 면역 염색을 위하여 각각의 항원에 맞는 전처리 과정을 진행한다. 표피층과 진피층 형성을 확인하기 위해서 multi-cytokerain 항체와 vimentin 항체를 반응시키고, 표피층의 basal layer 형성과 basement membrane 형성을 확인하기 위해서 cytokeratin 14와 type IV collagen 항체를 반응시켰다. 멜라닌 세포의 위치과 멜라닌 형성을 확인하기 위해서 HMB 45 항체를 반응 시켰다. 각각의 항체는 항온에서 20분 반응 시켰으며, biotinylated secondary antibody와 streptavidin-peroxidase를 반응 시키고, Hydrogen peroxide와 Nickel Solution이 첨가된 DAB 용액을 반응 시켜 발색시켰다. Fast red 용액에서 counter staining 후 Dehydration하고 mounting 하였다. 마지막으로 Olympus 사의 BX41 현미경을 통해서 관찰하였다. 도 13a는 본 발명의 피부세포 공배양 방법으로 배양된 세포를 동물 시험 진행 후 H&E와 mulit-cytokeratin, HMB45, collagen type-1, vimentin, E-cad 면역 염색한 결과이다. 도 13b는 정상 피부와 본 발명에 따라 in vivo 형성된 피부조직을 비교한 사진이다. 피부각질세포, 섬유아세포, 멜라닌 색소세포의 혼합 공동 배양후 동물 시험 결과 진피와 표피의 형성 뿐만 아니라 정상 피부와 유사한 형태의 멜라닌 세포분포를 보였다. 따라 서, 본 발명에 따라 혼합 공동배양된 세포가 정상피부와 매우 유사한 형태의 피부재생효과를 나타냄을 알 수 있다.In vivo skin formation test of mixed co-cultured cells is performed, and nude mice are sacrificed, and the formed tissues are fixed in formalin to prepare paraffin tissue sections. After deparaffinization and hydration, pretreatment procedures for each antigen are performed for antigen antibody immunostaining. To confirm epidermal and dermal layer formation, multi-cytokerain and vimentin antibodies were reacted, and cytokeratin 14 and type IV collagen antibodies were reacted to confirm basal layer formation and basement membrane formation. HMB 45 antibody was reacted to confirm the location of melanocytes and melanin formation. Each antibody was reacted at room temperature for 20 minutes, and then reacted with biotinylated secondary antibody and streptavidin-peroxidase, followed by reaction with DAB solution containing Hydrogen peroxide and Nickel Solution. After counter staining in fast red solution, dehydration and mounting were performed. Finally, it was observed through a Olympus BX41 microscope. Figure 13a is a result of immunostaining of H & E and mulit-cytokeratin, HMB45, collagen type-1, vimentin, E-cad after culturing the cells cultured by the skin cell co-culture method of the present invention. 13b is a photograph comparing normal skin and skin tissue formed in vivo according to the present invention. After co-culture of keratinocytes, fibroblasts and melanocytes, the animal test showed melanin distribution similar to normal skin as well as the formation of dermis and epidermis. Therefore, it can be seen that the cells co-cultured according to the present invention exhibit a skin regeneration effect very similar to that of normal skin.

이와 대조적으로, Keratinocyte 만을 단독으로 배양하거나 Keratinocyte와 섬유아세포를 각각 단독 배양후 혼합하여 동물시험을 진행하였다. 도 14는 Keratinocyte 만을 단독으로 배양하여 동물 시험진행 후 H&E와 mulit-cytokeratin 면역 염색한 결과이다. 표피층이 아주 미약하게 형성되고 Multi-cytokeratine 면역 염색결과 형성된 표피층이 매우 얇고 제대로 자리 잡지 못했음을 알수 있다. 도 15는 Keratinocyte와 섬유아세포를 각각 단독으로 배양하여 1:1 비율로 함께 투여하여 동물 시험 진행 후 H&E (가), 사람의 표피세포표지자인 판-사이토케라틴 (나), 사이토케라틴14 (다), 바이멘틴 (라), 콜라젠 타입IV (마) 각각의 항체 염색 결과이다. 표피세포만의 결과와 비교하였을때 basement membrane(콜라젠 타입IV)의 형성도 유도되고, 표피와 진피층의 형성도 이루어졌으나, 멜라닌 색소 세포의 부제로 피부색이 표현되지 못하였다.In contrast, only Keratinocytes were cultured alone, or Keratinocytes and fibroblasts were cultured alone and then mixed. FIG. 14 shows the results of H & E and mulit-cytokeratin immunostaining after culturing only Keratinocytes alone. The epidermal layer was formed very weakly, and the epidermal layer formed by the multi-cytokeratine immunostaining was very thin and poorly located. FIG. 15 shows that Keratinocytes and fibroblasts were cultured alone and administered together in a 1: 1 ratio, and then H & E (A), human epidermal cell markers, plate-cytokeratin (B), cytokeratin 14 (C) Antibodies staining results of, vimentin (LA), collagen type IV (MA) respectively. Compared with the result of epidermal cells alone, formation of basement membrane (collagen type IV) was induced and epidermal and dermal layers were formed, but skin color could not be expressed by the melanin cell.

이상 설명한 바와 같이, 본 발명에 따르면 하나의 공여부위로부터 분리된 각종 피부세포를 혼합배양함으로써, 세포상호간의 물질교환(paracrine effect)에 의해 무혈청 배지에서도 모든 세포가 잘 자라며, 각각의 세포를 배양하기 위해서 특성화된 배지가 아닌 배지에서도 잘 자라며, 단독배양시 세포수가 너무 적어서 자라지 못하는 경우에도 잘 자라며, 멜라닌 색소세포의 동결보관과 해동은 단독 배양시에는 거의 불가능했으나 혼합 공동배양과 동결의 경우 해동후에도 잘자라며, 시험 관내(in vitro) 섬유아세포의 배양에서 유도 되어지는 SMA(smooth muscle actin)의 발현이 혼합 공동 배양에서는 유도 되지 않으며 (즉, 분화가 유도 되지 않은 섬유아세포의 배양이 가능하며), 상기 혼합배양된 피부세포들을 포함하는 세포치료제는 종래의 표피세포(Keratinocyte)로만 된 세포치료제보다 더 월등한 피부상처치유 효과를 나타냈다.As described above, according to the present invention, by mixing and culturing various skin cells isolated from one donor site, all cells grow well in a serum-free medium by paracrine effect between cells and culture each cell. In order to grow well in a medium other than the specialized medium to grow, it grows well even if the cell number is too small to grow when cultured alone, freezing and thawing melanin pigment cells was almost impossible in single culture, but thawing in the case of mixed co-culture and freezing It grows well afterwards, and the expression of smooth muscle actin (SMA), which is derived from in vitro fibroblast cultures, is not induced in mixed co-cultures (i.e., culture of fibroblasts without differentiation is possible). Cell therapy comprising the mixed cultured skin cells, only epidermal cells (Keratinocyte) It showed a better skin healing effect than the cell therapy.

도 1은 본 발명에 따라 혼합배양한 일차배양(P=1) 및 계대배양(P=2~5)에서의 세포 모양을 관찰한 사진이다.1 is a photograph observing the cell shape in the primary culture (P = 1) and subculture (P = 2 to 5) mixed culture in accordance with the present invention.

도 2는 본 발명에 따라 혼합배양한 경우와 섬유아세포와 표피세포를 단독으로 배양한 경우를 비교한 사진이다.2 is a photograph comparing the case of mixed culture and the case of culturing fibroblasts and epidermal cells alone according to the present invention.

도 3은 본 발명에 따른 혼합배양에서 세포의 혼합 비율을 달리하여 시험한 결과이다.Figure 3 is a test result by varying the mixing ratio of the cells in the mixed culture according to the present invention.

도 4는 혈청(serum)이 첨가된 배지와 혈청이 없는 배지에서는 표피세포 단독배양과 표피세포와 섬유아세포가 함께 배양된 경우를 비교한 사진이다.FIG. 4 is a photograph comparing the culture of epidermal cells alone and the culture of epidermal cells and fibroblasts in a medium to which serum is added and a medium without serum.

도 5는 본 발명에 따라 혼합배양된 세포들의 동결보관 및 해동후 세포 생존율과 세포 상태를 확인한 사진이다.5 is a photograph confirming cell viability and cell state after cryopreservation and thawing of cells cultured according to the present invention.

도 6은 본 발명에 따른 계대수 2의 혼합 공동 배양한 세포를 면역 형광 염색한 사진이다.Figure 6 is a photograph of immunofluorescence staining of co-cultured cells of passage number 2 according to the present invention.

도 7은 본 발명에 따른 계대수 2의 혼합 공동 배양한 세포를 면역 형광 염색한 사진이다.Figure 7 is an immunofluorescence stained picture of passage co-culture of passage number 2 according to the present invention.

도 8은 본 발명에 따른 계대수 3의 혼합 공동 배양한 세포를 면역 형광 염색한 사진이다.8 is an immunofluorescence stained image of passage co-cultured cells of passage 3 according to the present invention.

도 9는 본 발명에 따른 계대수 3의 혼합 공동 배양한 세포를 면역 형광 염색한 사진이다.9 is a photograph of immunofluorescence staining of cells co-cultured with passage number 3 according to the present invention.

도 10은 본 발명에 따른 계대수 4의 혼합 공동 배양한 세포를 면역 형광 염 색한 사진이다.10 is an immunofluorescence stained picture of passage co-cultured cells of passage 4 according to the present invention.

도 11은 본 발명에 따른 혼합 공동 배양한 세포에서 α-SMA(α-smooth muscle actin)이 발현되는지를 확인한 사진이다.11 is a photograph confirming that α-SMA (α-smooth muscle actin) is expressed in mixed co-cultured cells according to the present invention.

도 12는 본 발명에 따라 혼합 공동 배양된 세포의 누드 마우스에서의 in vivo 피부형성능을 관찰한 사진이다.Figure 12 is a photograph of in vivo skin formation ability in nude mice of mixed co-cultured cells according to the present invention.

도 13은 본 발명의 피부세포 공배양 방법으로 배양된 세포를 동물 시험 진행 후 H&E와 mulit-cytokeratin, HMB45, collagen type-1, vimentin, E-cad 면역 염색한 결과이다.13 is a result of immunostaining of H & E and mulit-cytokeratin, HMB45, collagen type-1, vimentin, and E-cad after culturing the cells cultured by the skin cell co-culture method of the present invention.

도 14는 표피세포(Keratinocyte) 만을 단독으로 배양하여 동물 시험진행 후 H&E와 mulit-cytokeratin 면역 염색한 결과이다.FIG. 14 shows the results of H & E and mulit-cytokeratin immunostaining after culturing only epidermal cells (Keratinocyte) alone.

도 15는 표피세포와 섬유아세포를 각각 단독으로 배양후 혼합하여 동물 시험 진행 후 H&E (가), 사람의 표피세포표지자인 판-사이토케라틴 (나), 사이토케라틴14 (다), 바이멘틴 (라), 콜라젠 타입IV (마) 각각의 항체 염색 결과이다.Fig. 15 shows that epidermal cells and fibroblasts alone are cultured and mixed, and then, after animal testing, H & E (A), human epidermal cell markers, plate-cytokeratin (B), cytokeratin 14 (C), and bimentin (L). ), Collagen type IV (e) antibody staining results of each.

Claims (8)

자가(autologous) 피부 조직에서 유래된 하나의 공여 부위(donor site)에서 분리된 표피세포(Keratinocyte), 멜라닌세포(Melanocyte), 섬유아세포(Fibroblast) 및 혈관내피세포(Endothelial cell)를 무혈청 배지(serum-free media)에서 단독배양시 필요한 사이토카인(cytokine)이나 성장인자(growth factor)의 공급없이 세포상호간의 물질교환(paracrine effect)에 의해 혼합배양하는 것을 특징으로 하는 피부세포 공배양 방법.Epidermal cells (Keratinocytes), melanocytes (Melanocytes), Fibroblasts and Endothelial cells isolated from one donor site derived from autologous skin tissue were serum-free medium ( Method for co-culture of skin cells, characterized in that the mixed culture by the paracrine effect between the cells without supplying the cytokine (cytokine) or growth factor (growth factor) required for the sole culture in serum-free media. 제1항에 있어서, 상기 하나의 공여 부위의 크기는 0.5-2cm2 인 것을 특징으로 하는 피부세포 공배양 방법.The method of claim 1, wherein the size of the one donor site is a skin cell co-culture method, characterized in that 0.5-2cm 2 . 제 1항에 있어서, 상기 표피세포(Keratinocyte) 및 멜라닌세포(Melanocyte)는 상기 공여 부위의 표피층에서 분리하고, 상기 섬유아세포(Fibroblast) 및 혈관내피세포(Endothelial cell)는 상기 공여 부위의 진피층에서 분리된 것을 특징으로 하는 피부세포 공배양 방법.The method of claim 1, wherein the epidermal cells (Keratinocyte) and melanocytes (Melanocyte) are separated from the epidermal layer of the donor site, the fibroblast and endothelial cells (endothelial cells) are separated from the dermal layer of the donor site Skin cell co-culture method characterized in that. 삭제delete 제 1항에 있어서, 상기 표피세포+멜라닌세포 : 섬유아세포+혈관내피세포의 비율이 15:1 내지 25:1로 혼합배양하는 것을 특징으로 하는 피부세포 공배양 방법.The method of claim 1, wherein the ratio of epidermal cells + melanocytes: fibroblasts + vascular endothelial cells is cultured in a mixed culture of 15: 1 to 25: 1. 제 1항에 있어서, 섬유아세포의 단독배양에서 유도되어지는 SMA(smooth muscle actin)의 발현이 유도되지 않는 것을 특징으로 하는 피부세포 공배양 방법.The method of claim 1, wherein the expression of smooth muscle actin (SMA) induced in the culture of fibroblasts alone is not induced. 삭제delete 제 1, 2, 3, 5, 또는 6항 중 어느 한 항의 방법에 따라 공배양된 표피세포(Keratinocyte), 멜라닌세포(Melanocyte), 섬유아세포(Fibroblast) 및 혈관내피세포(Endothelial cell)를 포함하는 상처치유용(wound healing) 세포치료제 조성물.Including epidermal cells (Keratinocyte), melanocytes (Melanocyte), Fibroblast and Endothelial cells co-cultured according to any one of claims 1, 2, 3, 5, or 6 Wound healing cell therapeutic composition.
KR1020070076025A 2007-07-27 2007-07-27 Skin cell co-culture method and cell therapeutic composition using same KR100927374B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020070076025A KR100927374B1 (en) 2007-07-27 2007-07-27 Skin cell co-culture method and cell therapeutic composition using same
PCT/KR2008/004300 WO2009017321A2 (en) 2007-07-27 2008-07-23 Co-culture method of skin cells and cell therapy composition using the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020070076025A KR100927374B1 (en) 2007-07-27 2007-07-27 Skin cell co-culture method and cell therapeutic composition using same

Publications (2)

Publication Number Publication Date
KR20090011957A KR20090011957A (en) 2009-02-02
KR100927374B1 true KR100927374B1 (en) 2009-11-19

Family

ID=40305035

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020070076025A KR100927374B1 (en) 2007-07-27 2007-07-27 Skin cell co-culture method and cell therapeutic composition using same

Country Status (2)

Country Link
KR (1) KR100927374B1 (en)
WO (1) WO2009017321A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101738808B1 (en) 2015-03-06 2017-05-22 아주대학교산학협력단 Composition for regulating cutaneous pigmentation derived from endothelial cells or secretory factors from endothelial cells and method for screening skin whitening agents
KR102499154B1 (en) 2022-07-06 2023-02-14 주식회사 클리셀 Manufacturing method of artificial skin using cells differentiated from induced pluripotent stem cells
KR102543340B1 (en) 2022-07-06 2023-06-16 주식회사 클리셀 Manufacturing device of artificial skin using cells differentiated from induced pluripotent stem cells

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007040252A1 (en) 2006-09-11 2008-06-12 Gerlach, Jörg, Prof. Dr. Device for electronically flow-controlled distribution of tissue regenerating cell in sterile suspension across an area for further growth comprises electronically pressure/flow controlled spray head enabling controlled pump driven spraying
DE102011100450B8 (en) 2011-04-27 2013-10-17 Jörg Gerlach Apparatus for spraying cells, making the apparatus, method for spraying with the apparatus and a cell suspension sprayed with the apparatus
MY179888A (en) * 2012-06-20 2020-11-18 Univ Kebangsaan Malaysia Autologous tissue-engineered human skin construct and a method for producing thereof
KR102212623B1 (en) * 2014-04-16 2021-02-09 (주)아모레퍼시픽 Skin-improving material controlling expression of cadherin11 or N-cadherin and method for screening the material
US10420802B2 (en) 2015-12-10 2019-09-24 Aesthetics Biomedical, Inc. Topical formulation for skin care
AU2017283496B2 (en) 2016-06-14 2020-07-16 Renovacare Sciences Corp. Modular device for cell spraying

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035850A1 (en) * 2001-10-26 2003-05-01 Celltran Limited Cell transfer substrate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035850A1 (en) * 2001-10-26 2003-05-01 Celltran Limited Cell transfer substrate

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Angiogenesis, 2004, Vol.7, pp.295-305.
Tissue Eng. 2005, Vol.11, pp.1023-1033.*
논문4: Biomaterials*

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101738808B1 (en) 2015-03-06 2017-05-22 아주대학교산학협력단 Composition for regulating cutaneous pigmentation derived from endothelial cells or secretory factors from endothelial cells and method for screening skin whitening agents
KR102499154B1 (en) 2022-07-06 2023-02-14 주식회사 클리셀 Manufacturing method of artificial skin using cells differentiated from induced pluripotent stem cells
KR102543340B1 (en) 2022-07-06 2023-06-16 주식회사 클리셀 Manufacturing device of artificial skin using cells differentiated from induced pluripotent stem cells

Also Published As

Publication number Publication date
WO2009017321A3 (en) 2009-04-02
WO2009017321A2 (en) 2009-02-05
KR20090011957A (en) 2009-02-02

Similar Documents

Publication Publication Date Title
KR100927374B1 (en) Skin cell co-culture method and cell therapeutic composition using same
US7306943B2 (en) Keratinocytes useful for the treatment of wounds
Omoto et al. The use of human mesenchymal stem cell–derived feeder cells for the cultivation of transplantable epithelial sheets
Bello et al. Tissue-engineered skin: current status in wound healing
US6126935A (en) Pellets obtained from cell cultures of keratinocytes and their use in wound healing
US9592257B2 (en) Complete human skin organ generated from culture-expanded cells
Scuderi et al. The clinical application of autologous bioengineered skin based on a hyaluronic acid scaffold
US20160129044A1 (en) Use of mesothelial cells in tissue bioengineering and artificial tissues
JP2010505580A (en) Cultured melanocytes on biopolymers
Zhang et al. Cryopreserved skin epithelial cell sheet combined with acellular amniotic membrane as an off-the-shelf scaffold for urethral regeneration
EP0980270B1 (en) Dermal sheath tissue in wound healing
EP0681608B1 (en) Therapeutic applications of chimeric organogenesis
US6585969B1 (en) Non-viable keratinocyte cell composition or lysate for promoting wound healing
Hakim et al. Use of biodegradable mesh as a transport for a cultured uroepithelial graft an improved method using collagen gel
RU2342164C2 (en) Skin equivalent and method for its production
Liu et al. High yields of autologous living dermal equivalents using porcine gelatin microbeads as microcarriers for autologous fibroblasts
WO2006001778A1 (en) Formation of tissue engineered human skin using hpd as biomaterials
RU2010028C1 (en) Method of skin integument regeneration in critically burnt patients
Ivan et al. Perinatal Cells and Biomaterials for Wound Healing
PARTS Model for the In-Vitro Generation of Human Epidermal Autografts for Potential Use in Treatment of Sickle Cell Leg Ulcers

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120907

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20131030

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20140917

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20151106

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20161017

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20171206

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20181105

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20191107

Year of fee payment: 11